

**REMARKS**

The foregoing cancels claims 1-104 without prejudice or disclaimer. Applicant reserves the right to pursue the subject matter of these claims in one or more applications with the same rights of priority as the instant application.

The foregoing adds claims 105-145. Support for these claims is found throughout the specification as filed, as illustrated in the following table.

Claim	Specification
105	Pages 21-22, 30
106	Page 30
107	Page 30
108	Page 19
109-110, 132-133, 142-143	Pages 1-5, 7, 14
111, 134, 144	Pages 22-28
112-114	Pages 30-32
115-118	Page 34
119-123, 126-127, 136-137	Pages 29, 31-32
124	Pages 37-39
125	Pages 37-39
128, 138	Pages 37-38
129, 139	Page 38

Claim	Specification
130-131, 140-141	Pages 20-21
135	Page 8
145	Page 8

Applicant respectfully request entry of these amendments, and examination of claims 105-145 on their merits.

**Response to Restriction Requirement**

In response to the restriction requirement set forth in the Office Action mailed January 10, 2007, Applicant hereby provisionally elects the subject matter of Group III, *e.g.*, a palindromic probe, with traverse. In the foregoing claims, claims 113 and 114 recite palindromic probes.

This election is made with traverse in as much as Applicant respectfully urges that claims 105-145, or at least claims 105-123, be examined together with claims 113 and 114. Claims 105-123 are directed to peptide probes, specific embodiments of which include palindromic probes. Claim 124 is directed to a composition comprising a peptide probe according to claim 105. Claims 125-144 are directed to methods using a peptide probe according to claim 105. Claim 145 is directed to a kit comprising a peptide probe according to claim 105. Because each of the pending claims recites a peptide probe according to claim 105, Applicant believes that examining all claims together would not present an unreasonable burden to the Examiner.

Should there be any questions regarding this submission, or should any issue remain, the Examiner is invited to telephone the undersigned attorney of record in order to advance prosecution.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check or credit card payment form being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741. If any extensions of time are needed for timely acceptance of papers submitted herewith, Applicant hereby petitions for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extensions fees to Deposit Account No. 19-0741.

Respectfully submitted,

Date February 9, 2007

FOLEY & LARDNER LLP  
Customer Number: 22428  
Telephone: (202) 295-4094  
Facsimile: (202) 672-5399

By Courtenay C. Brinckerhoff

Courtenay C. Brinckerhoff  
Attorney for Applicant  
Registration No. 37,288